125 related articles for article (PubMed ID: 22836584)
21. A thioredoxin reductase inhibitor induces growth inhibition and apoptosis in five cultured human carcinoma cell lines.
Zhao F; Yan J; Deng S; Lan L; He F; Kuang B; Zeng H
Cancer Lett; 2006 May; 236(1):46-53. PubMed ID: 15982805
[TBL] [Abstract][Full Text] [Related]
22. Inhibition of both thioredoxin reductase and glutathione reductase may contribute to the anticancer mechanism of TH-302.
Li S; Zhang J; Li J; Chen D; Matteucci M; Curd J; Duan JX
Biol Trace Elem Res; 2010 Sep; 136(3):294-301. PubMed ID: 19838642
[TBL] [Abstract][Full Text] [Related]
23. Cancer cell death induced by phosphine gold(I) compounds targeting thioredoxin reductase.
Gandin V; Fernandes AP; Rigobello MP; Dani B; Sorrentino F; Tisato F; Björnstedt M; Bindoli A; Sturaro A; Rella R; Marzano C
Biochem Pharmacol; 2010 Jan; 79(2):90-101. PubMed ID: 19665452
[TBL] [Abstract][Full Text] [Related]
24. Structure-activity relationship studies of ethyl 2-amino-6-bromo-4-(1-cyano-2-ethoxy-2-oxoethyl)-4H-chromene-3-carboxylate (HA 14-1), an antagonist for antiapoptotic Bcl-2 proteins to overcome drug resistance in cancer.
Doshi JM; Tian D; Xing C
J Med Chem; 2006 Dec; 49(26):7731-9. PubMed ID: 17181155
[TBL] [Abstract][Full Text] [Related]
25. Discovery of New Monocarbonyl Ligustrazine-Curcumin Hybrids for Intervention of Drug-Sensitive and Drug-Resistant Lung Cancer.
Ai Y; Zhu B; Ren C; Kang F; Li J; Huang Z; Lai Y; Peng S; Ding K; Tian J; Zhang Y
J Med Chem; 2016 Mar; 59(5):1747-60. PubMed ID: 26891099
[TBL] [Abstract][Full Text] [Related]
26. Sublethal concentrations of diverse gold compounds inhibit mammalian cytosolic thioredoxin reductase (TrxR1).
Omata Y; Folan M; Shaw M; Messer RL; Lockwood PE; Hobbs D; Bouillaguet S; Sano H; Lewis JB; Wataha JC
Toxicol In Vitro; 2006 Sep; 20(6):882-90. PubMed ID: 16510263
[TBL] [Abstract][Full Text] [Related]
27. Benzimidazol-2-ylidene gold(I) complexes are thioredoxin reductase inhibitors with multiple antitumor properties.
Rubbiani R; Kitanovic I; Alborzinia H; Can S; Kitanovic A; Onambele LA; Stefanopoulou M; Geldmacher Y; Sheldrick WS; Wolber G; Prokop A; Wölfl S; Ott I
J Med Chem; 2010 Dec; 53(24):8608-18. PubMed ID: 21082862
[TBL] [Abstract][Full Text] [Related]
28. Inhibition of thioredoxin reductase by mansonone F analogues: Implications for anticancer activity.
Liu Z; Huang SL; Li MM; Huang ZS; Lee KS; Gu LQ
Chem Biol Interact; 2009 Jan; 177(1):48-57. PubMed ID: 18822278
[TBL] [Abstract][Full Text] [Related]
29. Synthesis and biological evaluation of 2'-oxo-2,3-dihydro-3'H- spiro[chromene-4,5'-[1,3]oxazolidin]-3'yl]acetic acid derivatives as aldose reductase inhibitors.
Rapposelli S; Da Settimo F; Digiacomo M; La Motta C; Lapucci A; Sartini S; Vanni M
Arch Pharm (Weinheim); 2011 Jun; 344(6):372-85. PubMed ID: 21319207
[TBL] [Abstract][Full Text] [Related]
30. Discovery and biochemical characterization of Plasmodium thioredoxin reductase inhibitors from an antimalarial set.
Theobald AJ; Caballero I; Coma I; Colmenarejo G; Cid C; Gamo FJ; Hibbs MJ; Bass AL; Thomas DA
Biochemistry; 2012 Jun; 51(23):4764-71. PubMed ID: 22612231
[TBL] [Abstract][Full Text] [Related]
31. NHC gold halide complexes derived from 4,5-diarylimidazoles: synthesis, structural analysis, and pharmacological investigations as potential antitumor agents.
Liu W; Bensdorf K; Proetto M; Abram U; Hagenbach A; Gust R
J Med Chem; 2011 Dec; 54(24):8605-15. PubMed ID: 22091836
[TBL] [Abstract][Full Text] [Related]
32. Small molecule inhibitors of mammalian thioredoxin reductase.
Cai W; Zhang L; Song Y; Wang B; Zhang B; Cui X; Hu G; Liu Y; Wu J; Fang J
Free Radic Biol Med; 2012 Jan; 52(2):257-65. PubMed ID: 22064364
[TBL] [Abstract][Full Text] [Related]
33. Current Progresses in Metal-based Anticancer Complexes as Mammalian TrxR Inhibitors.
Cheng Y; Qi Y
Anticancer Agents Med Chem; 2017; 17(8):1046-1069. PubMed ID: 28270080
[TBL] [Abstract][Full Text] [Related]
34. 1-Benzopyran-4-one antioxidants as aldose reductase inhibitors.
Costantino L; Rastelli G; Gamberini MC; Vinson JA; Bose P; Iannone A; Staffieri M; Antolini L; Del Corso A; Mura U; Albasini A
J Med Chem; 1999 Jun; 42(11):1881-93. PubMed ID: 10354396
[TBL] [Abstract][Full Text] [Related]
35. Emerging protein targets for anticancer metallodrugs: inhibition of thioredoxin reductase and cathepsin B by antitumor ruthenium(II)-arene compounds.
Casini A; Gabbiani C; Sorrentino F; Rigobello MP; Bindoli A; Geldbach TJ; Marrone A; Re N; Hartinger CG; Dyson PJ; Messori L
J Med Chem; 2008 Nov; 51(21):6773-81. PubMed ID: 18834187
[TBL] [Abstract][Full Text] [Related]
36. Noble metal targeting of thioredoxin reductase--covalent complexes with thioredoxin and thioredoxin-related protein of 14 kDa triggered by cisplatin.
Prast-Nielsen S; Cebula M; Pader I; Arnér ES
Free Radic Biol Med; 2010 Dec; 49(11):1765-78. PubMed ID: 20851179
[TBL] [Abstract][Full Text] [Related]
37. A sugar-modified phosphole gold complex with antiproliferative properties acting as a thioredoxin reductase inhibitor in MCF-7 cells.
Viry E; Battaglia E; Deborde V; Müller T; Réau R; Davioud-Charvet E; Bagrel D
ChemMedChem; 2008 Nov; 3(11):1667-70. PubMed ID: 18759235
[No Abstract] [Full Text] [Related]
38. Cell line-directed screening assay for inhibitors of thioredoxin reductase signaling as potential anti-cancer drugs.
Kunkel MW; Kirkpatrick DL; Johnson JI; Powis G
Anticancer Drug Des; 1997 Dec; 12(8):659-70. PubMed ID: 9448705
[TBL] [Abstract][Full Text] [Related]
39. Synthesis of various 3-nitropropionamides as Mycobacterium tuberculosis isocitrate lyase inhibitor.
Sriram D; Yogeeswari P; Methuku S; Vyas DR; Senthilkumar P; Alvala M; Jeankumar VU
Bioorg Med Chem Lett; 2011 Sep; 21(18):5149-54. PubMed ID: 21840711
[TBL] [Abstract][Full Text] [Related]
40. Gold(I) complex of N,N'-disubstituted cyclic thiourea with in vitro and in vivo anticancer properties-potent tight-binding inhibition of thioredoxin reductase.
Yan K; Lok CN; Bierla K; Che CM
Chem Commun (Camb); 2010 Nov; 46(41):7691-3. PubMed ID: 20623063
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
